中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
8期
1295-1299
,共5页
周玲%程煜凤%李文英%马桂芝
週玲%程煜鳳%李文英%馬桂芝
주령%정욱봉%리문영%마계지
左旋多巴%盐酸苄丝肼%微囊漂浮片%制备工艺
左鏇多巴%鹽痠芐絲肼%微囊漂浮片%製備工藝
좌선다파%염산변사정%미낭표부편%제비공예
Levodopa%Benserazide%Microcapsules floating tablets%Preparation process
目的::优选左旋多巴微囊漂浮片的处方。方法:高效液相色谱法测定左旋多巴与苄丝肼的含量,以漂浮片释放度得分为指标,采用正交试验优选左旋多巴微囊漂浮片的处方,并对其体外释药特性进行评价。结果:建立的测定左旋多巴胃内漂浮片中左旋多巴与苄丝肼含量的高效液相色谱法,符合方法学要求。优化的微囊漂浮片处方组成为硬脂酸:主药:丙烯酸树脂:HPMC=2∶5∶2∶1,平均片重为550 mg。验证试验结果表明该微囊漂浮片具有漂浮、缓释、可分剂量使用等特性。结论:优选出的复方左旋多巴微囊漂浮片处方合理,生产工艺稳定、可行。
目的::優選左鏇多巴微囊漂浮片的處方。方法:高效液相色譜法測定左鏇多巴與芐絲肼的含量,以漂浮片釋放度得分為指標,採用正交試驗優選左鏇多巴微囊漂浮片的處方,併對其體外釋藥特性進行評價。結果:建立的測定左鏇多巴胃內漂浮片中左鏇多巴與芐絲肼含量的高效液相色譜法,符閤方法學要求。優化的微囊漂浮片處方組成為硬脂痠:主藥:丙烯痠樹脂:HPMC=2∶5∶2∶1,平均片重為550 mg。驗證試驗結果錶明該微囊漂浮片具有漂浮、緩釋、可分劑量使用等特性。結論:優選齣的複方左鏇多巴微囊漂浮片處方閤理,生產工藝穩定、可行。
목적::우선좌선다파미낭표부편적처방。방법:고효액상색보법측정좌선다파여변사정적함량,이표부편석방도득분위지표,채용정교시험우선좌선다파미낭표부편적처방,병대기체외석약특성진행평개。결과:건립적측정좌선다파위내표부편중좌선다파여변사정함량적고효액상색보법,부합방법학요구。우화적미낭표부편처방조성위경지산:주약:병희산수지:HPMC=2∶5∶2∶1,평균편중위550 mg。험증시험결과표명해미낭표부편구유표부、완석、가분제량사용등특성。결론:우선출적복방좌선다파미낭표부편처방합리,생산공예은정、가행。
To optimize the formula of levodopa microcapsules floating tablets. Methods:The contents of levodopa and benserazide in the microcapsules floating tablets were determined by HPLC simultaneously. The release rate as the index, an orthogonal design was used to optimize the formula and preparation technology of levodopa microcapsules floating tablets. The release property of the microcapsules floating tablets was evaluated. Results:The HPLC method for the in vitro determination of levodopa and benserazide in the floating tablets met the methodological requirements. The selected formula was as following:the amount ratio of stearic acid, the drugs, acrylic resin and HPMC was 2∶5∶2∶1. The average weight of the tablets was 550 mg. The results of validated tests showed that the microcapsules floating tablets had floating and sustained release property, which could be used by divided dose. Conclusion: The optimized formula of the microcapsules floating tablets is reasonable, and the production process is stable and feasible.